**6. References**


A good cellular practice on anticancer drugs requires the best selections of cell line and model system, the best matched measurement methodology, and the most optimized lag

Abou-Issa, HM.; Alshafie, GA.; Seibert, K.; Koki, AT.; Masferrer, JL. & Harris, RE. (2001).

Arun, B. & Goss, P. (2004). The role of COX-2 inhibition in breast cancer treatment and

Assaraf, YG. (2007). Molecular basis of antifolate resistance. *Cancer Metastasis Rev.* Vol.26,

Bardin, A.; Boulle, N.; Lazennec, G.; Vignon, F. & Pujol, P. (2004). Loss of ERbeta expression

Barnhart, K.; Coutifaris, C. & Esposito, M. (2001). The pharmacology of methotrexate. *Expert* 

Brandes, LJ. & Hermonat, MW. (1983). Receptor status and subsequent sensitivity of

Ciocca, DR. & Roig, LM. (1995). Estrogen receptors in human nontarget tissues: biological

Clemons, M. & Goss, P. (2001). Estrogen and the risk of breast cancer. *N Engl J Med. Vol.*344,

Cody, V.; Luft, JR.; Pangborn. W. & Gangjee, A. (2003). Analysis of three crystal structure

DuMond, JWJ.; Singh, KP. & Roy, D. (2001). Regulation of the growth of mouse Leydig cells

Fox, EM.; Davis, RJ. & Shupnik, MA. (2008). ERbeta in breast cancer--onlooker, passive

Gangjee, A.; Yang J. & Queener SF. (2006). Novel non-classical C9-methyl-5-substituted-2,4-

Graffner-Nordberg, M.; Kolmodin, K.; Aqvist, J.; Queener, SF. & Hallberg, A. (2004). Design,

Gustafsson, JA. (2003). What pharmacologists can learn from recent advances in estrogen

signalling. *Trends Pharmacol Sci.* Vol.24, No.9, pp. 479–485

player, or active protector? Steroids. Vol.73, No.11, pp. 1039-1051

as a common step in estrogen-dependent tumor progression. *Endocr Relat Cancer,*

subclones of MCF-7 human breast cancer cells surviving exposure to

determinations of a 5-methyl-6-N-methylanilino pyridopyrimidine antifolate complex with human dihydrofolate reductase. *Acta Crystallogr D Biol Crystallogr*.

by the inactive stereoisomer, 17alphaestradiol: Lack of correlation between the elevated expression of ERalpha and difference in sensitivity to estradiol isomers.

diaminopyrrolo[2,3-d]pyrimidines as potential inhibitors of dihydrofolate reductase and as anti-opportunistic agents. *Bioorg Med Chem*. Vol.14, No.24, pp.

synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii. *Eur J Pharm Sci*. Vol.22, No.1,

mammary carcinogenesis. *Anticancer Res*. Vol.21, No.5, pp. 3425-3432 Arun, B.; Zhang, H, & Mirza, NQ. (2001). Growth inhibition of breast cancer cells by

celecoxib. *Breast cancer Res treat.* Vol.69, p. 234

*Opin Pharmacother.* Vol.2, No.3, pp. 409–417

diethylstilbestrol. *Cancer Res*. Vol.43, No.6, pp. 2831-2835

and clinical implications. *Endocr Rev*. Vol.16, No.1, pp. 35-62

prevention. *Semin Oncol*. Vol.31, Suppl. 7, pp. 22-29

Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of

time to look at the result for acquiring the most precise and accurate conclusion.

**6. References** 

No.1, pp. 153-181.

No.4, pp. 276–285

8341-8351

pp. 43-54

Vol.59, No.9, pp. 1603-1609

*Oncol Rep*, Vol.8, No.4, pp. 899-902

Vol.11, No.3, pp. 537-551


Remarks in Successful Cellular Investigations for

pp. 689-692.

No.2, pp. 233-239.

No.15, pp. 2734-2742

155–162.

pp. 55–62.

559.

667-673

*J Surg Res*. Vol.147, No.2, pp. 240-246

resistance. *Int J Hematol*. Vol.66, No.4, pp. 459-477

inhibitor of COX-2. *J Med Chem*. Vol.43, No.5, pp. 775-777

*and Applied Pharmacology.* Vol.140, pp. 211-218

Fighting Breast Cancer Using Novel Synthetic Compounds 101

Shirazi, F.H.; Molepo, M.; Stewart, D.J. & Goel, R. (1996). Cisplatin and its metabolites

Shirazi, F.H.; Shokrzadeh, M. & Hossinzadeh, L. (2005) Cellular cytotoxicity of arsenic and

Shirazi, F.H.; Shokrzadeh, M.; Abdollahi, M.; Rahimi, FB.; & Hossinzadeh, L. (2005).

Shokrzadeh, M.; Shirazi, F.H.; Abdollahi, M.; Abadi, A.G. & Asgarirad, H. (2006).

Singh, B.; Cook, KR.; Vincent, L.; Hall, CS.; Berry, JA.; Multani, AS. & Lucci, A. (2008).

Skliris, GP.; Parkes, AT.; Limer, JL.; Burdall, SE.; Carder, PJ. & Speirs, V. (2002). Evaluation

Takemura, Y.; Kobayashi, H. & Miyachi, H. (1997). Cellular and molecular mechanisms of

Talley, JJ.; Brown, DL.; Carter, JS.; Graneto, MJ.; Koboldt, CM.; Masferrer, JL.; Perkins, WE.;

Tamaddon, A.M.; Shirazi, F.H. & Moghimi, H.R. (2007). Preparation of

Van Heerde, WL.; Robert-Offerman, S.; Dumont, E.; Hofstra, L.; Doevendans, PA.; Smits, JF.;

Vic, P.; Vignon, F.; Derocq, D. & Rochefort H. (1982). Effect of Estradiol on the Ultrastructure

models of cellular membranes. *Journal of Daru*, Vol.15, No.2, pp. 61-69 Välimaa, H.; Savolainen, S.; Soukka, T.; Silvoniemi, P.; Mäkelä, S.; Kujari, H.; Gustafsson, JA.

cytotoxicity, accumulation and efflux in human ovarian carcinoma cells. *Toxicology* 

its association with cellular glutathione. *Chemistry: An Indian Journal*, Vol.1, No.10,

Relationship of cellular glutathione concentration with the cytotoxicity of acetaminophen in different cell lines. *Int. J. Biol. Biotech.*, Vol.2, No.2, pp. 397-402. Shirazi, F.H.; Yazdanpanah, H.; Khoshjoo, F. & Hossinzadeh, L. (2006). Pistachio extracts

effects on the aflatoxin B1 cytotoxicity in HepG2 cells. *Int. J. Pharmacology*, Vol.2,

Relationship of glutathione concentrations with cytotoxicity of cisplatin in different cell lines after confront vitamin C and E. *Pakistan Journal of Biological Sciences*, Vol.9,

Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells.

of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. *J Pathol.* Vol.197, No.2, pp.

resistance to antifolate drugs: new analogues and approaches to overcome the

Rogers, RS.; Shaffer, AF.; Zhang, YY.; Zweifel, BS. & Seibert, K. (2000). 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective

oligodeoxynucleotide encapsulated cationic liposomes and release study with

& Laine, M. (2004). Estrogen receptor-β is the predominant estrogen receptor subtype in human oral epithelium and salivary glands. *J Endocrinol.* Vol.180, No.1,

Daemen, MJ. & Reutelingsperger, CP. (2000). Markers of apoptosis in cardiovascular tissues: focus on Annexin V. *Cardiovasc Res*. Vol.45, No.3, pp. 549-

of the MCF7 Human Breast Cancer Cells in Culture. *Cancer Res*. Vol.42, No.2, pp.

and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. *Breast Cancer Res* Vol.10, No.5, R74


observational prospective study. *Breast Cancer Res* Vol.10, No.5, R74 Penning, TD.; Talley, JJ.; Bertenshaw, SR.; Carter, JS.; Collins, PW.; Docter, S.; Graneto, MJ.;

Lett. Vol.9, No,13, pp. 1773-1778.

*Steroid Biochem Mol Biol*. Vol.3, pp. 1-32

cell lines. *Cancer Res.* Vol.48, No.17, pp. 4827–4833

(CHO) cell line. *Pajohandeh*. Vol.9, No.40, pp. 191-197

pulegium on cancer cells. *Journal of Daru,* Vol. 12, No. 3

Vol.91, pp. 129-150

23l6

and node-negative breast cancer classified according to molecular subtypes: an

Lee, LF.; Malecha, JW.; Miyashiro, JM.; Rogers, RS.; Rogier, DJ.; Yu, SS.; Anderson, GD.; Burton, EG.; Cogburn, JN.; Gregory, SA.; Koboldt, CM.; Perkins, WE.; Seibert, K.; Veenhuizen, AW.; Zhang, YY. & Isakson, PC. (1997). Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). *J Med Chem*. Vol.40, No.9, pp. 1347-1365 Prasit, P.; Wang, Z.; Brideau, C.; Chan, CC.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans,

JF.; Ford-Hutchinson, AW.; Gauthier, JY.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Léger, S.; Mancini. J.; O'Neill, GP.; Ouellet, M.; Percival, MD.; Perrier, H.; Riendeau, D.; Rodger, I. & Zamboni, R. (1999). The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem

C.E. (1998). Evaluation of apoptosis in four human tumour cell lines with differing

Friesen, RW.; Gordon, R.; Greig, G.; Guay, J.; Mancini, J.; Ouellet, M.; Wong, E.; Xu, L.; Boyce, S.; Visco, D.; Girard, Y.; Prasit, P.; Zamboni, R.; Rodger, IW.; Gresser, M.; Ford-Hutchinson, AW.; Young, RN.; Chan, CC. (2001). Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit

Raaphorst, G.P.; Mao, J.; Yang, H.; Goel, R.; Niknafs, B.; Shirazi, F.H.; Yazdi, M.H. & Ng,

sensitivities to cisplatin. *AntiCancer Research.* Vol.18, No.4C, pp. 2945-2951. Riendeau, D.; Percival, MD.; Brideau, C.; Charleson, S.; Dubé, D.; Ethier, D.; Falgueyret, JP.;

Rosenberg, B. (1977). Noble metal complexes in cancer chemotherapy*. Adv Exp Med Biol*.

Rosenberg, B. (1985). Fundamental studies with cisplatin. *Cancer*, Vol.55, No.10, pp. 2303-

Rosenberg, B.; VanCamp, L.; Trosko, JE.; & Mansour, VH. (1969). Platinum compounds: a new class of potent antitumour agents. *Nature,* Vol.222, No.5191, pp. 385-386 Roy, D. & Cai, Q. (2002). Estrogen, immunoactivation, gene damage, and development of

Russo, J.; Bradley, R.H.; McGrath, C. & Russo, I.H. (1977). Scanning and transmission

Shirazi, F.H. & Eftekhari, M. (2004). Cellular toxicity of cisplatin in Chiness hamster ovarian

Shirazi, F.H.; Ahmadi, N. & Kamalinejad, M. (2004). Evaluation of northern Iran Mentha

in collagen-coated cellulose sponge. *Cancer Res*. Vol.37, pp. 2004-2014 Scudiero, DA.; Shoemaker, RH.; Paull, KD.; Monks, A.; Tierney, S.; Nofziger, TH.; Currens,

breast, endometrial, ovarian, prostate, and testicular cancers. *Recent Res Devel* 

electron microscopy study of a human breast carcinoma cell line (MCF-7) cultured

MJ.; Seniff, D. & Boyd, MR. (1988). Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor

cyclooxygenase-2. *. J Pharmacol Exp Ther*. Vol.296, No.2, pp. 558-566


**6** 

*Iran* 

**Breast Cancer from Molecular Point of View:** 

Breast cancer is the most common female cancer, the second most common cause of cancer death in women, and the main cause of death in women ages 40 to 59 (1). It has been reported that mortality rate from breast cancer has been significantly greater in women whose cancer was first diagnosed during pregnancy compared with those who had never been pregnant (2). Nowadays, many women all over the world faced the challenge of living with breast cancer. The lifetime probability of developing breast cancer is one in six overall (3). High prevalence of breast cancer and high mortality rate of women who stricken by, appoint it among the most challenging subjects in the area of experiments. The two major types of breast cancer risks are objective and subjective factors. Objective breast cancer risk is defined as an estimated chance for bearing breast cancer based on scientifically established risk factors for the disease and is predictive of resultant health outcomes. Subjective breast cancer risk is identified as an individual's realization of her chance for getting breast cancer based on her own cognitive appraisal and is affected by depressive conditions. Objective BC risk had a limited but significant relationship with immune response and natural killer cell activity (NKCA), whereas Subjective risk was highly associated with psychological distress but was not associated with NKCA also the results

Many factors including prenatal conditions, diet, physical activity, estrogen exposure, body mass index, depression and quality of life have been mentioned as breast cancer risk factors. A positive family history is the main risk factor. Diet with high amounts of alcohol, fat, caffeine and red meat is a positive risk factor for bearing breast cancer, whereas phytoestrogens and high amounts of calcium/vitamin D can be effective to reduce it (5,6). Hormonal conditions stand among the most important factors. Prolonged exposure to and higher concentrations of endogenous estrogen; which is controlled and modulated by menarche, pregnancy, and menopause; increase the risk of breast cancer. Testosterone level has also showed some parallelism with higher rate of breast cancer in some studies, although not in all of them. Younger age of menarche and older age of first full-term pregnancy are associated with a higher risk of breast cancer. The data about the effects of oral contraceptives on breast cancer risk are controversial. Some studies show an increased risk of breast cancer in oral contraceptive users, whereas in some other researches, no significant difference was seen. The two newer researches didn't give any data which show

**1. Introduction** 

are still controversial (4).

**1.1 Breast cancer and risk factors** 

**Pathogenesis and Biomarkers** 

*Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran,* 

Seyed Nasser Ostad and Maliheh Parsa

